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In 2016, a total of 42,249 persons in the US died from drug overdoses involving opioids; the 
age-adjusted rate was 13.3 per 100,000 (CDC, 2018a). By 2017, the national drug overdose 
death rate rose by another 12% (CDC, 2018b).  
Death by drug poisoning is the leading cause of death due to injury in the state of Utah 
(UDOH, 2014). From 2013-2015, Utah ranked seventh in the nation for drug overdose deaths, 
the majority of which were opioid-related (CDC, 2018a). In 2017, the age-adjusted mortality 
rate from drug overdose in Utah was 15.5 per 100,000, putting the state above the national 
average of 14.9 per 100,000 (CDC, 2018b). 
Opioid overdose death rates in most of rural Utah far exceeds rates across the urban counties 
of the state (see Table 1 below). The higher rates of deaths in rural Utah is indeed concerning. 
Evidence indicates that rural areas are particularly hard hit due to limited access to care and 
resources (USDA, 2019). 
Distance from health services affects peoples’ ability to get treatment when they need it 
(Stulz, Pichler, Kawohl, & Hepp, 2018). This can affect the likelihood of someone recovering 
from a health emergency, particularly when respiratory failure occurs (Karra, Fink, & Canning, 
2017; Raknes, Hansen, & Hunskaar, 2013; Nicholl, West, Goodacre, & Turner, 2007). Opioids are 
known respiratory inhibitors, which means having access to nearby treatment is especially 
important in preventing opioid overdose deaths. Those deaths are already more common in 
rural U.S. regions (Mack, Jones, & Ballesteros, 2017). 
Access to emergency care is not the only thing that matters in rural areas. People in recovery 
and seeking support also need access to ongoing evidence-based treatments in order to stay 
well. A key component of this is medication-assisted treatment (MAT), which is the gold stan-
dard of evidence-based treatment recommended by the Substance Abuse and Mental Health 
Services Administration (SAMHSA) (SAMHSA, 2014). Rural areas in the U.S. have significantly 
fewer medication-assisted treatment programs than urban areas (Hirchak, & Murphy, 2017). 
Given that roughly one-third of American Indian and Alaska Native individuals live in rural 
regions of the U.S. (U.S. Census Bureau, 2017), these geographic trends also disproportion-
ately affect Native Americans living on reservations. Nationally, when compared to other 
racial groups, American Indian and Alaska Native populations have experienced the largest 
increases in drug and opioid overdose death rates between 1999 and 2015 (Joshi, Weiser, & 
Warren-Mears, 2015). Yet, a national analysis of treatment programs that directly serve Amer-
ican Indian and Alaska Native communities found that less than 30% of programs offer MAT 
like methadone and buprenorphine (Novins, Aarons, & Conti, et al., 2011). Utah is a large, rural 
state with eight tribal governments; health equity requires attention to both rural and tribal 
groups. 
The Opioid Crisis: Key trends
Rural Areas are Hard Hit 
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We applied USDA’s definition (USDA, 2019) 
to identify Utah counties as rural or ur-
ban. The combined 1999-2017 mortality 
data (CDC, 2018b) indicate that the aver-
age death rate in rural counties was 17.76 
(per 100,000 population) which was high-
er than that in urban counties (11.99 per 
100,000 population).1 Based on statistical 
results, we have evidence to conclude that 
rural counties differed from non-rural (ur-
ban) ones in opioid-induced drug overdose 
death rates.2 Table 1 further highlights 
this urban-rural divide in opioid overdose 
death rates in Utah. 
The high rates of overdose deaths in rural 
Utah call for immediate intervention, 
namely medicated-assisted treatment 
(MAT). MAT entails the use of FDA-ap-
proved medications to treat withdrawals 
and physical dependence, alongside be-
havioral therapy and counseling services. 
Access to MAT options affects overdose 
death rates in Utah.  In Figure 1, we present the mismatch between access to MAT 
resources and severity of opioid overdose deaths in Utah. The red triangles indicate 
buprenorphine providers and the black stars indicate methadone clinics. The color 
gradient on this map represents the severity of overdose rates: yellow indicating the 
lowest rate of overdose and red indicating the highest. The counties with insuffi-
cient data are colored grey. Treatment options are most highly concentrated on the 
Wasatch Front (i.e., the most urban counties in Utah), which have among the lowest 
rates of opioid overdose deaths. MAT treatment options in rural and tribal areas are 
limited or virtually unavailable, but show higher rates of opioid overdose deaths.  
Figure 1: Opioid Drug Overdose Death 
Rates by county (cumulative 1999-2017) 
Source: Authors’ analysis using CDC (2018a) data.
1 A sizeable number of counties in Utah reported mortality counts that were too small to be reliable. 
To address this problem of no reliable year-wise (annual) data for most counties in Utah, we combined 
mortality numbers between 1999 and 2017.
 2 We conducted a nonparametric statistical test (Mann Whitney test) to compare rural-urban county 
difference in mortality between 1999 and 2017.
MEDICATION-ASSISTED TREATMENT ACCESS IN UTAH
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Table 2 lists the three kinds of MAT approved for treatment of opioid use disorder 
(OUD): Methadone, Buprenorphine, and Naltrexone (SAMHSA, 2019a). These medica-
tions block the euphoric effect of drugs, relieve cravings, and stabilize brain chemis-
try without the negative side effects of the previously abused drug (SAMHSA, 2019b). 
Naloxone is a lifesaving overdose reversal drug, and is an evidence-based approach 
to preventing opioid mortality. Any healthcare professional licensed to prescribe 
medications can prescribe Naloxone. Additionally, if you, or people in your life, are at 
risk of opioid overdose, you can become trained to administer Naloxone. Additional 
information is available from: https://naloxone.utah.gov. You can also visit the 
websites listed below to find additional information on MAT providers and clinics.
• Methadone Clinics: http://www.opiateaddictionresource.com/treatment/metha-
done_clinic_directory/ut_clinics
• Buprenorphine Prescribers: https://www.samhsa.gov/medication-assisted-treat-
ment/practitioner-program-data/treatment-practitioner-locator
What can you do and what do you need to know?
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Table 1: Age-Adjusted Death Rates (per 100,000) by counties, 1999-2017, Utah 
Urban Counties Rural Counties 
Box Elder 10.70 Beaver* No Data 
Cache 8.06 Carbon 34.37 
Davis 10.84 Dagett No Data 
Salt Lake 14.88 Duchesne* 16.67 
Summit 8.32 Emery 22.63 
Tooele 15.28 Garfield No Data 
Utah 12.92 Grand* No Data 
Wasatch 9.88 Iron* 15.63 
Washington 14.19 Juab* 17.28 
Weber 14.78 Kane* 16.60 
Millard* 13.81 
Morgan No Data 
Piute* No Data 
Rich No Data 
San Juan* No Data 
Sanpete 15.93 
Sevier 13.28 
Uintah* 11.36 
Wayne No Data 
Urban Average 11.99 Rural Average 17.76 
Source: CDC (2018b) 
* Rural counties with reservations
gett
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Table 2: Medication Assisted Treatment (MAT) Options 
Type Description How to Obtain Treatment Length	of Treatment 
Methadone Methadone is a long-
acting opioid 
medication used to 
help people with 
OUDs by stopping 
physical withdrawal 
and cravings. It lasts 
24-36 hours, so it
must be taken daily. It
blocks the effects of
other opioids like
heroin. When taken as
prescribed by a
physician, it does not
produce any euphoria
or long-term health
problems, and is a
safe and effective
treatment (SAMHSA,
2019c).
In the beginning stages 
of Methadone treatment, 
patients are required to 
receive treatment under 
the supervision of a 
physician at a SAMHSA 
certified opioid 
treatment program (OTP). 
When patients reach 
consistent stability, they 
may be permitted to take 
Methadone at their 
homes in between 
program visits (SAMHSA, 
2019c). 
Minimum of 12 
months of daily 
dosing, but there is 
no maximum amount 
of time after which 
patients must stop 
methadone 
treatment. Stopping 
methadone must be 
done slowly over 
time, under the 
supervision of a 
physician (SAMHSA, 
2019c). 
Buprenorphine Buprenorphine is 
another opioid 
medication used to 
treat physical 
withdrawal and 
cravings among 
people with OUDs. It 
is also long-acting 
(24-37 hours) and 
must be taken daily. It 
blocks the effects of 
other opioids like 
heroin. A common 
brand name type of 
buprenorphine is 
In order to prescribe 
Buprenorphine, medical 
providers must be legally 
certified to prescribe 
Buprenorphine (SAMHSA, 
2019d). Likely, a 
prescription will not be 
available through one’s 
primary care provider, 
however, a list of 
providers is included in 
this fact sheet. 
Three phases:	
1. Introduction
Phase
2. Stabilization
Phase
3. Maintenance
Phase
The duration of each 
phase varies between 
individuals. Like 
methadone, there is 
no maximum time 
recommended for 
buprenorphine 
treatment. Stopping 
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“Suboxone,” which 
combines 
buprenorphine and 
naloxone. Similar to 
methadone, it does 
not produce euphoric 
feelings or health 
problems when it is 
dosed by a physician. 
It is a safe and 
effective treatment 
(SAMHSA, 2019d). 
buprenorphine must 
be done slowly over 
time, under the 
supervision of a 
physician (SAMHSA, 
2019d). 
Naltrexone Naltrexone is a non-
opioid medication 
used to treat opioid 
use disorder and 
alcohol use disorder. 
It blocks opioid 
receptors in the brain, 
but does not stop 
people with OUDs 
from physical 
withdrawal symptoms, 
and thus is not 
recommended for 
people with physical 
dependence on 
opioids. It can be 
taken orally every day 
or injected once per 
month (brand name 
injectable medication 
is called “Vivitrol”) 
(SAMHSA, 2019e). 
Naltrexone can be 
prescribed by any 
healthcare professional 
who is licensed to 
prescribe medications 
(SAMHSA, 2019e). 
There is no maximum 
treatment length for 
naltrexone. Treatment 
length and cessation 
should be decided 
between a patient 
and their prescribing 
healthcare provider.  
Source: SAMHSA (2018c-e) 
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